The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzyloxy-4-trifluoromethyl- coumarin, midazolam and docetaxel

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 6, 2014, Pages 865-874

  Mooiman, Kim D ^a   Maas Bakker, Roel F ^a   Hendrikx, Jeroen J M A ^b   Bank, Paul C D ^a   Rosing, Hilde ^b   Beijnen, Jos H ^a,b   Schellens, Jan H M ^a,c   Meijerman, Irma ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

complementary and alternative medicine; cytochrome P450 3A4; docetaxel; midazolam; pharmacokinetic interactions

Indexed keywords

7 BENZYLOXY 4 TRIFLUOROMETHYLCOUMARIN; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BETA CAROTENE; CYANOCOBALAMIN; CYTOCHROME P450 3A4; DOCETAXEL; GRAPE SEED EXTRACT; GREEN TEA EXTRACT; HERBACEOUS AGENT; MIDAZOLAM; PYRIDOXINE; UNCLASSIFIED DRUG; VALERIAN; 7-BENZYLOXY-4-TRIFLUOROMETHYLCOUMARIN; COUMARIN DERIVATIVE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; TAXOID; TEA;

ALTERNATIVE MEDICINE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ECHINACEA; ENZYME INHIBITION; ENZYME METABOLISM; GARLIC; GINKGO BILOBA; GINSENG; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; PREDICTIVE VALUE; SABAL; SILYBUM MARIANUM; TANDEM MASS SPECTROMETRY; METABOLISM; PHYSIOLOGY; TEA;

COMPLEMENTARY THERAPIES; COUMARINS; CYTOCHROME P-450 CYP3A; GINKGO BILOBA; GRAPE SEED EXTRACT; HUMANS; MICROSOMES, LIVER; MIDAZOLAM; MILK THISTLE; TAXOIDS; TEA;

EID: 84900475546     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12208     Document Type: Article

References (67)

1. Sparreboom A, et al. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004; 22: 2489-2503.
2. McCune JS, et al. Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer 2004; 12: 454-462.
3. Tascilar M, et al. Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist 2006; 11: 732-741.
4. Gupta D, et al. The use of dietary supplements in a community hospital comprehensive cancer center: implications for conventional cancer care. Support Care Cancer 2005; 13: 912-919.
5. Werneke U, et al. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 2004; 90: 408-413.
6. Beijnen JH, Schellens JH,. Drug interactions in oncology. Lancet Oncol 2004; 5: 489-496.
7. He SM, et al. Effects of herbal products on the metabolism and transport of anticancer agents. Expert Opin Drug Metab Toxicol 2010; 6: 1195-1213.
8. Anzenbacher P, Anzenbacherova E,. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001; 58: 737-747.
9. Modarai M, et al. Safety of herbal medicinal products: Echinacea and selected alkylamides do not induce CYP3A4 mRNA expression. Evid Based Complement Alternat Med 2011; 2011: 1-11.
10. Hansen TS, Nilsen OG,. In vitro CYP3A4 metabolism: inhibition by Echinacea purpurea and choice of substrate for the evaluation of herbal inhibition. Basic Clin Pharmacol Toxicol 2008; 103: 445-449.
11. Hellum BH, Nilsen OG,. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol 2008; 102: 466-475.
12. Hellum BH, et al. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 2007; 100: 23-30.
13. Yale SH, Glurich I,. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 2005; 11: 433-439.
14. Foster BC, et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003; 10: 334-342.
15. Modarai M, et al. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content. J Pharm Pharmacol 2007; 59: 567-573.
16. Engdal S, Nilsen OG,. In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. Phytother Res 2009; 23: 906-912.
17. Ho BE, et al. Effects of garlic on cytochromes P450 2C9- and 3A4-mediated drug metabolism in human hepatocytes. Sci Pharm 2010; 78: 473-481.
18. Zou L, et al. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002; 71: 1579-1589.
19. Foster BC, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001; 4: 176-184.
20. Etheridge AS, et al. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 2007; 73: 731-741.
21. He N, Edeki T,. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther 2004; 11: 206-212.
22. Patel J, et al. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 2004; 11: 262-277.
23. Hao M, et al. Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS ONE 2008; 3: e2697.
24. Liu Y, et al. Influence of ginsenoside Rh1 and F1 on human cytochrome P450 enzymes. Planta Med 2006; 72: 126-131.
25. Liu Y, et al. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci 2006; 91: 356-364.
26. Budzinski JW, et al. Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products. Can J Physiol Pharmacol 2007; 85: 966-978.
27. Beckmann-Knopp S, et al. Inhibitory effects of silibinin on cytochrome P450 enzymes in human liver microsomes. Pharmacol Toxicol 2000; 86: 250-256.
28. Doehmer J, et al. Assessment of drug-drug interaction for silymarin. Toxicol in Vitro 2008; 22: 610-617.
29. Jancova P, et al. Silybin is metabolized by cytochrome P450 2C8 in vitro. Drug Metab Dispos 2007; 35: 2035-2039.
30. Kosina P, et al. Effect of silybin and its glycosides on the expression of cytochromes P450 1A2 and 3A4 in primary cultures of human hepatocytes. J Biochem Mol Toxicol 2005; 19: 149-153.
31. Sridar C, et al. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 2004; 32: 587-594.
32. Venkataramanan R, et al. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000; 28: 1270-1273.
33. Zuber R, et al. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res 2002; 16: 632-638.
34. Ruhl R, et al. Carotenoids and their metabolites are naturally occurring activators of gene expression via the pregnane X receptor. Eur J Nutr 2004; 43: 336-343.
35. Yasui H, et al. Evidence for singlet oxygen involvement in rat and human cytochrome P450-dependent substrate oxidations. Drug Metab Pharmacokinet 2002; 17: 416-426.
36. Wang K, et al. Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway. Biochem Pharmacol 2008; 75: 2204-2213.
37. Wang K, et al. Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci 2006; 92: 51-60.
38. Muto S, et al. Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450. Mutat Res 2001; 479: 197-206.
39. Nishikawa M, et al. Effects of continuous ingestion of green tea or grape seed extracts on the pharmacokinetics of midazolam. Drug Metab Pharmacokinet 2004; 19: 280-289.
40. Netsch MI, et al. Induction of CYP1A by green tea extract in human intestinal cell lines. Planta Med 2006; 72: 514-520.
41. Mirkov S, et al. Effects of green tea compounds on irinotecan metabolism. Drug Metab Dispos 2007; 35: 228-233.
42. Gaudineau C, et al. Inhibition of human P450 enzymes by multiple constituents of the ginkgo biloba extract. Biochem Biophys Res Commun 2004; 318: 1072-1078.
43. Yeung EY, et al. Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab Dispos 2008; 36: 2270-2276.
44. Li L, et al. Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res 2009; 26: 872-882.
45. He N, et al. Induction of CYP3A in primary cultures of human hepatocytes by ginkgolides A and B. Clin Exp Pharmacol Physiol 2007; 34: 632-635.
46. Satsu H, et al. Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals. J Agric Food Chem 2008; 56: 5366-5373.
47. Raucy JL,. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 2003; 31: 533-539.
48. Gutmann H, et al. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression? Planta Med 2006; 72: 685-690.
49. Moore LB, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000; 97: 7500-7502.
50. Komoroski BJ, et al. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004; 32: 512-518.
51. Miller VP, et al. Fluorometric high-throughput screening for inhibitors of cytochrome P450. Ann N Y Acad Sci 2000; 919: 26-32.
52. Parkinson A, et al. System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes vs liver microsomes vs recombinant enzymes. Drug Metab Pharmacokinet 2010; 25: 16-27.
53. Ogilvie BW, et al. In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450. In:, Rodrigues AD, ed. Drug-Drug Interactions. New York: Informa Healthcare USA Inc., 2008: 231-358.
54. Winslow LC, Kroll DJ,. Herbs as medicines. Arch Intern Med 1998; 158: 2192-2199.
55. Stresser DM, et al. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos 2002; 30: 845-852.
56. Mooiman KD, et al. Development and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures. Biomed Chromatogr 2013; 27: 1107-1116.
57. Walsky RL, Obach RS,. Validated assays for human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 647-660.
58. Sparreboom A, et al. Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab Dispos 1996; 24: 655-658.
59. Hendrikx JJ, et al. Quantification of docetaxel and its metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2013; 27: 1925-1934.
60. Royer I, et al. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996; 56: 58-65.
61. European Medicines Agency. Guideline on the investigation of drug interactions 2010. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2012/07/WC500129606.pdf (accessed November 12, 2012).
62. Vogel HG, et al. eds. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. New York: Springer, 2006.
63. Renwick AB, et al. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms. Xenobiotica 2000; 30: 955-969.
64. Stresser DM, et al. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 2000; 28: 1440-1448.
65. Bjornsson TD, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003; 43: 443-469.
66. Goey AKL, et al. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treat Rev 2013; 39: 773-783.
67. Strandell J, et al. An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 2004; 11: 98-104.